Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.62 |
| ▸ | TNF | P01375 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.57 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780041 | 0.90 | ADORA2B (0.65) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL39131 | 0.86 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL680306 | 0.86 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline, (S)- SCHEMBL1495100 | 0.86 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6785799 | 0.86 | ADORA2B (0.64) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8061728 | 0.85 | ADORA2B (0.63) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8686678 | 0.85 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6780377 | 0.85 | ADORA2B (0.62) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6780935 | 0.85 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL10517408 | 0.85 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0484785-B1 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST ROUSSEL PHARMA (US) | 1996-05-22 | — | — | EP | claimed |
| US-9493463-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493463-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9035050-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035050-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140296263-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296263-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140121226-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-0573617-A4 | — | — | 1994-02-09 | — | — | EP | disclosed |
| EP-0573617-A1 | MODULATION OF CELLULAR RESPONSE TO EXTERNAL STIMULI | Fred Hutchinson Cancer Research Center (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992021344-A2 | MODULATION OF CELLULAR RESPONSE TO EXTERNAL STIMULI | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0493682-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0490181-A1 | Use of xanthines for preparation of a medicament having immunosuppressing activity | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0484785-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4713455-A | FOR OBSTRUCTIVE DISORDERS OF THE RESPIRATORY TRACT | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-12-15 | — | — | US | disclosed |
| US-4616020-A | TREATING OBSTRUCTIVE RESPIRATORY DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0075850-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING VICINAL DIHYDROXYALKYL XANTHINES, PROCESS FOR THE PREPARATION OF THE XANTHINES AND THE APPROPRIATE INTERMEDIATES THEREFOR | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-12-18 | — | — | EP | disclosed |
| EP-0075850-A2 | Pharmaceutical preparations containing vicinal dihydroxyalkyl xanthines, process for the preparation of the xanthines and the appropriate intermediates therefor | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20140121226-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, CXCR4, CXCR3 | ADORA2B 24/4885TNF 1024/4885USP2 3890/4885 |
| US-20140296263-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, CXCR3, CXCR4 | ADORA2B 179/4885TNF 2183/4885USP2 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.